Showing results (541-550 of 803) with videos related to
Sort By:
Pageof 81
Journal of Alzheimer'S Disease Reports|August 8, 2024
Long-Term Effects of the Multicomponent Program BrainProtect® on Cognitive Function: One-Year Follow-Up in Healthy AdultsMichelle Celine Kunkler, Julia Maria Falkenreck, Anja Ophey, et al.Journal of Alzheimer'S Disease Reports|August 8, 2024
An Investigation of the Inflammatory Landscape in the Brain and Bone Marrow of the APP/PS1 MouseKishore Chittimalli, Stephen Adkins, Sanjay Arora, et al.Journal of Alzheimer'S Disease Reports|April 28, 2025
The relationship of 18F-FDG-PET to other common biomarkers of dementia in a clinical cohort with memory deficitsKatharina Woyk, Niels Hansen, Jens Wiltfang, et al.Journal of Alzheimer'S Disease Reports|March 27, 2025
Brain morphology mediating the effects of common genetic risk variants on Alzheimer's diseaseEsmee M Breddels, Yelyzaveta Snihirova, Ehsan Pishva, et al.Journal of Alzheimer'S Disease Reports|April 4, 2025
Cerebrospinal fluid Visinin-like protein-1 was associated with the relationship of body mass index with Alzheimer's disease pathology and cognition in non-demented elderlyYayu Wang, Siqi Yu, Man Zhang, et al.Journal of Alzheimer'S Disease Reports|March 4, 2025
Epigenetics as a link between environmental factors and dementia riskAdamantia Koulouri, Anthony S ZannasJournal of Alzheimer'S Disease Reports|March 4, 2025
Centella asiatica improves cognitive function and alters the hippocampal metabolome of aged Tg2576 and wild-type miceDonald G Matthews, Mona Khorani, Gerd Bobe, et al.Journal of Alzheimer'S Disease Reports|March 4, 2025
Lower expression of BIN1's neuronal isoform in vulnerable excitatory neurons increases risk in Alzheimer's diseaseRajesh Ranganathan, Siwen Li, Georgy Sapozhnikov, et al.Journal of Alzheimer'S Disease Reports|March 4, 2025
Cardio and cerebrovascular diseases risk among Alzheimer's disease patients and racial/ethnic disparities, based on Hawaii Medicare dataChathura Siriwardhana, Enrique Carrazana, Kore Liow, et al.Journal of Alzheimer'S Disease Reports|March 4, 2025
A 52-week, open-label, observational study evaluating tolerability, efficacy and physicians satisfaction of rivastigmine oral solution in Alzheimer's disease in TaiwanChuo-Yu Lee, Wen-Fu Wang, Jung-Lung Hsu, et al.Pageof 81